MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-05-2026
National Research Corporation ROCE Ratio 2011-2026 | NRC
Annual ROCE Ratio National Research Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 161.47 | 112.5 | 81.8 | 64.61 | 58.91 | 66.36 | 59.33 | 57.9 | 36.02 | 35.01 | 31.14 | 27.85 | 28.41 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 161.47 | 27.85 | 63.18 |
Quarterly ROCE Ratio National Research Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113.52 | 82.51 | 97.12 | 68.81 | 86.01 | 80.17 | 70.16 | 41.32 | 57.72 | 56.91 | 61.61 | 47.5 | 63.3 | 62.72 | 61.99 | 48.24 | 66.93 | 69.82 | 68.21 | 50.52 | 81.59 | 93.97 | 110.4 | 94.47 | 142.5 | 159.46 | 169.25 | 135.62 | 143.53 | 103.41 | 72.15 | 28.38 | 37.25 | 38.2 | 37.29 | 27.01 | 35.83 | 35.79 | 35.89 | 25.25 | 33.41 | 32.74 | 31.37 | 24.93 | 33.33 | 33.58 | 34.09 | 26.17 | 36.12 | 37.67 | 39.15 | 29.86 | 37.41 | 35.01 | 32.71 | 24.71 | 7.55 | 6.9 | 10.26 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 169.25 | 6.9 | 59.48 |
ROCE Ratio of other stocks in the Diagnostics research industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-89.9 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
25.0 | $ 121.87 | 3.06 % | $ 37 B |  USA |
 |
Burning Rock Biotech Limited
BNR
|
-41.81 | $ 20.67 | -8.13 % | $ 222 M |  China |
 |
Accelerate Diagnostics
AXDX
|
62.7 | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
114.15 | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-360.98 | - | -13.05 % | $ 7.29 M | USA |
 |
Check-Cap Ltd.
CHEK
|
1809.55 | - | - | $ 9.42 M |  Israel |
 |
Chembio Diagnostics
CEMI
|
-132.81 | - | 0.22 % | $ 16.8 M | USA |
 |
CareDx, Inc
CDNA
|
-10.16 | $ 21.42 | -4.46 % | $ 1.14 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-2.26 | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
-181.44 | - | -11.32 % | $ 2.94 M | USA |
|
Akumin
AKU
|
58.25 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
-22.04 | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
-236.6 | $ 1.56 | 6.85 % | $ 2.08 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-8.59 | - | - | $ 19.8 B | USA |
 |
Castle Biosciences
CSTL
|
1.9 | $ 25.05 | 2.0 % | $ 696 M | USA |
 |
Global Cord Blood Corporation
CO
|
12.48 | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-18.87 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-347.69 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-15.41 | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
0.8 | $ 183.88 | 3.92 % | $ 9.11 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
9.75 | - | - | $ 10.7 B | USA |
 |
Danaher Corporation
DHR
|
8.93 | $ 194.75 | 0.5 % | $ 139 B | USA |
 |
Interpace Biosciences
IDXG
|
18.26 | $ 2.0 | -9.09 % | $ 8.85 M | USA |
 |
Myriad Genetics
MYGN
|
-105.22 | $ 5.08 | 1.6 % | $ 470 M | USA |
 |
Heska Corporation
HSKA
|
-4.81 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-219.45 | - | -20.0 % | $ 1.06 M | USA |
 |
NeoGenomics
NEO
|
-9.11 | $ 8.35 | 2.33 % | $ 1.07 B | USA |
 |
Neogen Corporation
NEOG
|
-51.22 | $ 9.51 | 2.92 % | $ 2.06 B | USA |
 |
Medpace Holdings
MEDP
|
116.53 | $ 520.6 | 0.96 % | $ 15 B | USA |
 |
Illumina
ILMN
|
-35.1 | $ 134.5 | 1.34 % | $ 21.4 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
6.33 | $ 29.7 | 3.74 % | $ 20 B |  Niderland |
 |
Precipio
PRPO
|
-8.25 | $ 28.3 | -2.41 % | $ 45.4 M | USA |
 |
Fulgent Genetics
FLGT
|
-6.52 | $ 16.26 | 0.81 % | $ 492 M | USA |
 |
Guardant Health
GH
|
440.3 | $ 90.36 | 5.44 % | $ 11.3 B | USA |
 |
Senseonics Holdings
SENS
|
-111.94 | $ 6.77 | - | $ 282 M | USA |
 |
QIAGEN N.V.
QGEN
|
8.07 | - | - | $ 10.6 B | Niderland |
 |
Anixa Biosciences
ANIX
|
-77.18 | $ 2.91 | 2.83 % | $ 94.4 K | USA |
 |
Soleno Therapeutics
SLNO
|
2.09 | $ 52.78 | 0.4 % | $ 2.68 B | USA |
 |
Biomerica
BMRA
|
-125.14 | $ 2.18 | -0.91 % | $ 5.01 M | USA |
 |
Motus GI Holdings
MOTS
|
-443.13 | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
4.69 | $ 119.68 | 3.55 % | $ 9.87 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
16.06 | $ 270.68 | 1.62 % | $ 22.5 B | USA |
 |
Neuronetics
STIM
|
-140.48 | $ 1.42 | 1.43 % | $ 93.7 M | USA |
 |
Celcuity
CELC
|
-171.24 | $ 122.46 | -2.23 % | $ 5.73 B | USA |
 |
Lantheus Holdings
LNTH
|
28.52 | $ 83.82 | -0.12 % | $ 5.66 B | USA |
 |
Thermo Fisher Scientific
TMO
|
14.5 | $ 526.6 | 2.05 % | $ 199 B | USA |
 |
Trinity Biotech plc
TRIB
|
0.08 | $ 0.75 | 6.62 % | $ 61.9 M | Irlanda |
 |
Quest Diagnostics Incorporated
DGX
|
21.7 | $ 195.02 | 1.86 % | $ 21.6 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-185.74 | $ 6.4 | 23.79 % | $ 5.04 M | USA |